Patent is Filed for Device To Ease Catheter Insertion
Urovalve, of Newark, N.J., has filed a patent for a device that facilitates insertion of catheters, such as Foley catheters, the company said.
Industry News
Anti-CMV Drug Cleared for Pediatric Transplant Patients
The FDA has approved Valcyte (valganciclovir hydrochloride) for the prevention of cytomegalovirus (CMV) disease in pediatric kidney and heart transplant recipients (aged four months to 16 years) who are at high risk of developing the disease.
Orally Dissolving Tablets for Diabetic Gastroparesis Cleared
Salix Pharmaceuticals has receiving marketing clearance for Metozolv (metoclopramide HCl) ODT (orally dissolving tablets) 5 mg and 10 mg orally disintegrating tablets for the relief of diabetic gastroparesis and symptomatic documented gastroesophageal reflux (GERD).
FDA Approves Aliskiren/Valsartan Combination Pill
FDA has approved Valturna (aliskiren and valsartan) tablets, which the drug’s maker, Novartis, of East Hanover, N.J., said is the first and only product to target two key points in the renin angiotensin aldosterone system (RAAS).
Tacrolimus Cleared for Use with MMF in Renal Transplant Patients
Astellas Pharma US, in Deerfield, Ill., has received approval for the use of Prograf (tacrolimus) in conjunction with mycophenolate mofetil (MMF) in kidney transplant recipients.
First and Only Topical Gel for Overactive Bladder Cleared
Watson Pharmaceuticals, Corona, Calif., has received approval for Gelnique (oxybutynin chloride) Gel 10%, the first and only topical gel for the treatment of overactive bladder (OAB).
Hyponatremia Drug Receives Marketing Clearance
The FDA has approved Samsca tablets (tolvaptan) to treat hyponatremia, one of the most common electrolyte disorders seen in hospitalized patients.
Panel Recommends Approval of Drug for Refractory Gout
The FDA’s Arthritis Drugs Advisory Committee has recommended that Krystexxa (pegloticase) be approved for treating refractory chronic gout.
Cook Medical to Market Pneumatic Lithotripter
As a result of a partnership with LMA Urology, of Gland, Switzerland, Cook Medical, of Bloomington, Ind., has added a new lithotripter to its kidney stone treatment line.
BPH Medication to Be Tested in an Extended Phase 3 Study
Æterna Zentaris Inc., of Quebec City, Canada, has announced the opening of an extended phase 3 study of cetrorelix, a treatment for benign prostatic hyperplasia (BPH).
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...